Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control

BACKGROUND: Approximately 3%–5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors. Crizotinib and ceritinib have demonstrated superior efficacy to platinum‐based chemotherapy as front‐line treatment for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shih‐Hao, Huang, Allen Chung‐Cheng, Wang, Chin‐Chou, Chang, Wen‐Chen, Liu, Chien‐Ying, Pavlidis, Stelios, Ko, Ho‐Wen, Chung, Fu‐Tsai, Hsu, Ping‐Chih, Guo, Yi‐Ke, Kuo, Chih‐Hsi Scott, Yang, Cheng‐Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885427/
https://www.ncbi.nlm.nih.gov/pubmed/31613427
http://dx.doi.org/10.1111/1759-7714.13221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885427/
https://www.ncbi.nlm.nih.gov/pubmed/31613427
http://dx.doi.org/10.1111/1759-7714.13221

Ejemplares similares